Media Center
29
2019
-
11
Innovation-driven lean development: Immunotech Biopharm was awarded the 2019 China Science and Technology Innovation Enterprise.
On November 28, the "2019 Second CSR Pioneer Forum and Corporate Social Responsibility" award ceremony, hosted by the International Financial News, was grandly held at the People's Daily in Beijing. This forum, themed "Benefiting Hearts and Goodness, Sustainable China," brought together experts, scholars, and representatives from various fields to discuss how enterprises can balance social and environmental interests while pursuing economic benefits, providing effective solutions for sustainable development and creating shared value.
Group photo of award winners
The selection for the Science and Technology Innovation Enterprise Award officially started on October 8. Since its launch, it has received widespread attention and enthusiastic participation from all sectors of society, with hundreds of well-known enterprises registering to participate. After nearly two months of online voting and expert review, Immunotech Biopharm was awarded the 2019 China Science and Technology Innovation Enterprise Award for its outstanding performance in continuous innovation and practice in the biopharmaceutical field.
Conference site
Stay true to the original aspiration and move forward towards dreams
Immunotech Biopharm is a national high-tech enterprise specializing in the research and development, technical application, and product transformation of immunotherapy drugs. Since its establishment in 2006, it has focused on applying advanced theories in immunology, cell biology, and genetics, combined with cutting-edge international technical experience, to research and develop immunotherapy, clinical applications, and biopharmaceuticals targeting major diseases such as malignant tumors.
After thirteen years of hard work, Immunotech Biopharm has established a complete R&D system from theoretical verification to experimental research, from in vitro experiments to animal experiments, and from safety evaluation to clinical research. Currently, over 4,000 patients have used EAL in Chinese hospitals.®The traceable records of the product confirm that its efficacy is superior to that of chemotherapy when used in combination, and it has effects in preventing recurrence and maintaining long-term survival. Liver cancer patients have achieved a survival period of up to ten years after receiving EAL treatment.®After thirteen years of hard work, Immunotech Biopharm people are finally delighted to see that tumor patients have the opportunity to improve their survival chances with the help of EAL, which is the best reward for us.®Guest speeches
Innovation leads cluster development
Immunotech Biopharm is one of the first companies in China to register immunocyte preparations as drugs and apply for new drug clinical research approval from the National Medical Products Administration. The core product EAL is currently the only immunocyte product approved to enter Phase II clinical trials for solid tumors in China. Clinical trial research has been conducted in 14 top-tier hospitals in Beijing, Tianjin, Henan, and Hebei, such as Xiehe and 301, which is expected to fill the gap in cell therapy for solid tumors in China and has milestone significance.
Immunotech Biopharm's core technology team consists of senior tumor immunologists, possessing strong professionalism and industry foresight. As a high-tech biopharmaceutical enterprise, a strong support and reserve of scientific research talent is crucial for the development of the enterprise. Currently, the R&D team has over a hundred members, with a solid foundation and experience in pharmaceutical theory knowledge, R&D, processes, and testing practices, establishing a systematic R&D platform in the field of T-cell immunotherapy drugs. Several immunocyte drugs have entered the preclinical research stage, covering treatment areas such as solid tumors and hematological tumors, and some R&D results have been applied for domestic and international patents.®As one of the earliest biopharmaceutical enterprises in China to enter and focus on the R&D and commercialization of immunotherapy drugs, Immunotech Biopharm relies on its leading technological development and the advantages of pharmaceutical leading enterprises. Its business has shown a trend of cluster development, focusing on expanding the strategic layout covering the entire industry chain of adoptive cell immunotherapy, striving to create the most comprehensive innovation platform system in China's biopharmaceutical field, the strongest R&D capabilities, and the best quality of industrial development, achieving stable and long-term development on the path of high-quality growth.
Roundtable forum
Seizing the opportunity to create brilliance
Guided by the corporate philosophy of "Letting life continue in our hands," Immunotech Biopharm has always focused on scientific research and technological innovation, continuously improving services, accelerating the construction of an open cell drug incubation platform that meets the highest domestic standards for cell GMP process, and striving to create the number one brand in the domestic cell technology field.
Immunotech Biopharm plans to complete the enrollment of all subjects in the second half of 2020 and finish the mid-term data analysis by the first half of 2021, applying for conditional approval for marketing from the National Medical Products Administration. At the same time, research work on expanding the indications for EAL and accelerating the preclinical research of pipeline products will be carried out, promoting the strategic layout covering the entire industry chain of adoptive cell immunotherapy, providing the most optimized treatment plans for a large number of cancer patients, and improving their survival status.
Immunotech Biopharm's R&D and production center in Beijing covers an area of over 7,500 square meters, mainly conducting preclinical and clinical R&D of immunocyte products, and supporting the initial market demand after product launch. All facilities have obtained the cleanroom inspection report issued by the Beijing Drug Inspection Institute. Regarding the six-hour transportation radius of EAL products, the company plans to successively establish R&D and production centers in Shanghai, Guangzhou, and other locations, and plans to establish production centers in densely populated cities such as Chengdu, Wuhan, Xi'an, and Shenyang, covering densely populated areas across the country, accelerating the progress of clinical trials and meeting future commercialization needs.
Immunotech Biopharm's award of the 2019 China Science and Technology Innovation Enterprise Award represents the encouragement and recognition from expert reviews and all sectors of society for Immunotech Biopharm's leading position in the industry and continuous innovation capabilities. In the future, Immunotech Biopharm will continue to drive lean development through innovation, establish itself with integrity, and achieve long-term goals with trust, integrating high standards and high quality into quality control, enterprise management, and industrial layout, providing safe and high-quality immunotherapy drugs for a large number of cancer patients, becoming a pioneer and leader in China's immunocyte therapy drugs, and benefiting human health.®扩大适应症的研究工作和加速管线产品的临床前研究工作，推进过继细胞免疫疗法全产业链覆盖的战略布局，为广大肿瘤患者提供最优化的过继细胞免疫疗法治疗方案，改善他们的生存现状。
永泰生物位于北京的研发及生产中心总面积逾7500平方米，主要进行免疫细胞产品的临床前及临床研发，并支撑产品上市后初期市场需求，所有设施均已取得北京市药检所发出的洁净厂房（区）检验报告书。针对EAL®产品的六小时运输半径，公司计划在上海、广州等地相继成立研发及生产中心，接下来计划在成都、武汉、西安及沈阳等人口密集的地区城市建立生产中心，覆盖全国人口稠密的地区，加速临床试验进度，并满足未来商业化需求。
永泰生物此次荣获2019年度中国科技创新企业奖，代表了专家评审和社会各界对永泰在行业中的领先地位以及持续创新能力的鼓励与认可。未来，永泰生物将继续以创新驱动精益发展，以诚立业，以信致远，将高标准、高质量融入品质管控、企业管理、产业布局等环节，为广大肿瘤患者提供安全高质的免疫治疗药物，成为中国免疫细胞类治疗药品的先行者与领导者，造福人类健康。